ArticlemBio2024
Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 58 citations in OpenAlex.
- Trial
- Article
- Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy.Cancer medicine · 2026Article
- Coal Dust Nanoparticles Induce Colitis-Like Lesions in Rats via Gut Microbiota Dysbiosis and P53/SCO2/SLC7A11-Mediated Epithelial Ferroptosis.Digestive diseases and sciences · 2026Article
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- Almond-Derived Peptide Fraction Alleviates DSS-Induced Colitis with Associated Anti-Inflammatory, Antioxidant, and Barrier-Restorative Effects.Foods (Basel, Switzerland) · 2026Article
- Akkermansia muciniphila supplementation alters inflammatory profiles across diverse models of colitis.Scientific reports · 2026Article
- Unveiling the Molecular Repertoire ofJournal of microbiology and biotechnology · 2026Review
- Jieduquyuziyin prescription for systemic lupus erythematosus: a system-level therapeutic strategy for immunological recalibration.Chinese medicine · 2026Review
- Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.Blood advances · 2026Article
- Association Between Gut Microbiota and HIV Infection Risk: Insights from Mendelian Randomization and 16S rRNA Amplicon Sequencing.Microorganisms · 2026Article
- Calcined lotus leaf-derived carbon dots: enhanced hemostasis, anti-inflammatory, immunomodulatory properties for ulcerative colitis management.Journal of nanobiotechnology · 2026Article
- Effectiveness of probiotic supplementation on growth performance, gut microbiota, and Salmonella reduction in broiler chicks challenged with Salmonella Typhimurium.Scientific reports · 2026Article
- Oral colon-targeted paeonol emulsion for ameliorating ulcerative colitis based on charge adsorption.Drug delivery and translational research · 2026Article
- Gut-Lung Axis Microbiome Dysbiosis and Cross-Domain Network Analysis in Bronchiectasis Complicated by Invasive Pulmonary Aspergillosis.Infection and drug resistance · 2026Article
- The shifting balance: innate lymphoid cell plasticity in chronic gut diseases.Frontiers in immunology · 2026Review
- Human Gut Commensal Bacteroides fragilis Suppresses Mucin Production and Alters Microbiota Composition Resulting in Accelerated Type 1 Diabetes in Mice.Immunology · 2026Article
- Navigating the duality of Akkermansia muciniphila.Nature microbiology · 2026Review
- Probiotic-based self-crosslinking bio-coating for the treatment of colitis by increasing probiotic colonization.Materials today. Bio · 2025Article
- A defined bacterial consortium and spatial transcriptomics highlight the complex interaction betweenGut microbes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
Abstract
Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the gastrointestinal tract. The etiology of IBD remains elusive, but the disease is suggested to arise from the interaction of environmental and genetic factors that trigger inadequate immune responses and inflammation in the intestine. The gut microbiome majorly contributes to disease as an environmental variable, and although some causative bacteria are identified, little is known about which specific members of the microbiome aid in the intestinal epithelial barrier function to protect from disease. While chemically inducing colitis in mice from two distinct animal facilities, we serendipitously found that mice in one facility showed remarkable resistance to disease development, which was associated with increased markers of epithelial barrier integrity. Importantly, we show that IMPORTANCE: The contribution of the gut microbiome to the balance between homeostasis and inflammation is widely known. Nevertheless, the etiology of inflammatory bowel disease, which is known to be influenced by genetics, immune response, and environmental cues, remains unclear. Unlocking novel players involved in the dictation of a protective gut, namely, in the microbiota component, is therefore crucial to develop novel strategies to tackle IBD. Herein, we revealed a synergistic interaction between two commensal bacterial strains,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.